Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Point-of-Care Uric Acid Testing

Samantha C. Shapiro, MD  |  March 1, 2023

In June 2022, I listened to several presentations on gout at EULAR’s European Congress of Rheumatology. Most began with data confirming a sad truth that we, as rheumatology providers, are all aware of: too many patients are taking subtherapeutic doses of urate-lowering therapy (ULT).1,2 Recommendations from the American College of Physicians in 2017 advocated for a treat-to-symptom approach, as opposed to the ACR, which advocates a treat-to-target approach (i.e. bringing the serum urate level below 6 mg/dL). The ACP deemed the evidence for monitoring serum urate (SU) levels insufficient, leading to mixed messaging to rheumatologists and other practitioners who treat patients with gout.3

Physician understanding isn’t the only barrier to good gout care. Patients—no matter how good their intentions—may struggle to obtain the frequent labs required for ULT dose titration.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

My best friend has been suffering from recurrent gout attacks for two years. He’s an educated, 37-year-old man. I referred him to an excellent rheumatologist with whom I trained. He went to the appointment and understood the game plan. He started allopurinol with flare prophylaxis months ago, but hasn’t been back to the clinic for repeat labs since. He knows he needs to go. But this father of a rambunctious 1-year-old works full time and travels frequently, and he just hasn’t found the time to return to the clinic. Hyperuricemia persists, and he continues to have gout flares.

All of this got me thinking. Why isn’t uric acid point-of-care (POC) testing a thing? Home monitoring exists for other burdensome situations, such as international normalized ratio (INR) monitoring. Wouldn’t this make sense for gout? Am I really the first person to ever think of this? In short, the answer is no. No, I’m not the first person to think about this. It exists.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

History

POC testing is generally defined as a diagnostic test and analysis performed where care is provided, close to or near the patient.

POC testing isn’t new. Urinalysis is more than 6,000 years old. Although Hippocrates is credited as the first uroscopist, the Sumerians and Babylonians documented urine assessments on clay tablets as early as 4,000 B.C.4 Synovial fluid crystal analysis is distinctly younger; microscopes of sufficient magnifying power were not invented until the late 17th century.5

Antoni van Leeuwenhoek described the appearance of monosodium urate crystals from a tophus in 1679, although their chemical composition was not elucidated until many years later.6 Interestingly, he also discovered bacteria by accident. He was a cloth merchant who simply wanted to take a better look at the cloth he sold—and lo and behold, the cloth was covered in microorganisms. What’s more, he discovered human sperm. He was analyzing the ejaculate of a patient with gonorrhea and compared it to his own.5 But I digress.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsEULAR/OtherGout and Crystalline ArthritisMeeting Reports Tagged with:EULARGoutpoint-of-careTestingUric acid

Related Articles

    Difficult Gout

    July 1, 2007

    “Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

    Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

    October 14, 2019

    Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

    New Draft Gout Guideline Released

    November 20, 2019

    ATLANTA—The authors of the new draft ACR treatment guideline for the management of gout presented the draft guideline on Nov. 13 at the 2019 ACR/ARP Annual Meeting. Based on evidence from more than 130 published studies, there are 42 recommendations, of which 16 were strong, including 27 for urate-lowering therapy (ULT) management, 13 of which…

    Lost and found

    Understanding the Role of Uric Acid in Gout

    September 6, 2022

    From the first substantial argument in the 19th century that uric acid played a role in gout, it took about 100 years for the medical community to accept its role in triggering acute inflammatory gout attacks. Two papers, both published in 1962, helped demonstrate the link between uric acid and acute gout attacks, quickly opening…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences